Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L) In the PETHEMA/GEM2012MENOS65 ...

In the draft guidance, the agency discusses how sponsors can leverage MRD and complete response rates as near-term efficacy measures and speed new therapies to market.

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing clinicians to make more informed decisions about therapy. MRD testing helps gauge ...

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an ...

Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves into one of the hottest topics in the hematologic malignancy space today: ...

Around the same time, Mack Fulwyler, an engineer working at Los Alamos National Laboratory, needed to separate particles, so he drew on existing techniques to create droplets to separate cells from a ...

The first detailed description of the microbiota and immune cells among asymptomatic Helicobacter pylori-infected individuals has been published by researchers at Karolinska Institutet. The results of ...

The initial diagnostic workup should include a history and physical examination, as well as some baseline laboratory studies (Figure 2-1). The initial diagnostic workup should include a history and ...